Ryan Crowe
Investor Relations Contact bij REGENERON PHARMACEUTICALS, INC.
Profiel
Ryan Crowe is currently the Head of Investor Relations at Regeneron Pharmaceuticals, Inc. Prior to this, he worked as the Senior Director of Investor Relations at Pfizer Inc. and as the Vice President of Investor Relations at Myovant Sciences Ltd.
He received his undergraduate degree from Drexel University and his MBA from The Leonard N Stern School of Business.
Actieve functies van Ryan Crowe
| Bedrijven | Functie | Begin |
|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | Investor Relations Contact | - |
Eerdere bekende functies van Ryan Crowe
| Bedrijven | Functie | Einde |
|---|---|---|
| MYOVANT SCIENCES LTD. | Investor Relations Contact | - |
| PFIZER, INC. | Public Communications Contact | - |
Opleiding van Ryan Crowe
| Drexel University | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
